CRPC
Metastatic castration-resistant prostate cancer
Advertisement
Patients with BRCA mutations had a higher risk of death, while patients with PTEN/TP53/RB1 mutations did not.
The panel explores the distinct roles of alpha and beta emitters in radiopharmaceutical therapy for prostate cancer care.
The expert panel discusses emerging biomarkers and treatment combinations for CRPC and mHSPC.
The evolving role of RLT and radium-223 in managing metastatic mHSPC and CRPC is discussed.
The panel examines the impact of the latest data from ARANOTE and PEACE-3 in part three of this roundtable.
The panelists discuss key considerations for patient selection in doublet and triplet therapies for mHSPC and CRPC.
In part one of this roundtable, the panel discusses advances in imaging and tailored treatment strategies for prostate cancer
The phase 3 trial evaluates combination mevrometostat in patients with mCRPC previously treated with abiraterone acetate.
The real-world analysis of olaparib for HRRm+ CRPC showed that earlier treatment resulted in higher PFS and OS.
Dr. Sartor offers insight on the efficacy of 177Lu-PSMA-617 in prolonging progression-free survival rates.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
The panelists examine the existing data for T cell engagers in CRPC and how the data might affect clinical practice.
The panel discusses the emerging field of PSMA-targeted alpha radioligand therapy, with a focus on HK2.
Part two of this roundtable features a discussion on the role of bone scans compared to the newer PSMA PET scans.
The first part of this roundtable focuses on the impact of recent research on clinical practice.
The fifth segment of the RLT roundtable explores recent clinical trials, including the VISION study.
In the final segment of this series, Drs. Morris, Garmezy, and Chen discuss the use of novel radiopharmaceuticals.
In the fourth part of this series, the panelists discuss barriers to the use of radium-223 and other radioligands.
In part 3 of this series, the panelists review the latest game-changing studies in prostate cancer and CRPC from ESMO 2024.
In the second part of this series, the decision-making process of considering ADT and doublet or triplet therapy is weighed.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.